公开(公告)号：US20230149381A1

公开(公告)日：2023-05-18

申请号：US17918829

申请日：2021-04-15

申请人： Eisai R&D Management Co., Ltd.

发明人： Kyoko NISHIBATA ,  Sayo FUKUSHIMA ,  Satoshi KAWANO ,  Saori MIYANO

IPC分类号： A61K31/4545 ,  A61K31/519 ,  A61K31/565 ,  A61P35/04

CPC分类号： A61K31/4545 ,  A61K31/519 ,  A61K31/565 ,  A61P35/04

摘要： Provided is a therapeutic agent for treating breast cancer that has developed resistance to administration of CDK4/6 inhibitors and estrogen antagonists, the agent containing 5-((2-(4-(1-(2-hydroxyethyl)piperidin-4-yl)benzamide)pyridin-4-yl)oxy)-6-(2-methoxyethox y)-N-methyl-1H-indole-1-carboxamide or a pharmacologically acceptable salt thereof.

公开(公告)号：US20230172924A1

公开(公告)日：2023-06-08

申请号：US18008304

申请日：2021-07-29

申请人： Eisai R&D Management Co., Ltd.

发明人： Satoshi KAWANO ,  Saori Miyano ,  Kyoko NISHIBATA ,  Sayo FUKUSHIMA

IPC分类号： A61K31/4545 ,  A61K31/565 ,  A61K31/4196 ,  A61K31/566 ,  A61P35/00

CPC分类号： A61K31/4545 ,  A61K31/565 ,  A61K31/4196 ,  A61K31/566 ,  A61P35/00

摘要： Disclosed is a therapeutic agent for breast cancer, said therapeutic agent comprising 5-((2-(4-(1-(2-hydroxyethyl)piperidin-4-yl)benzamide)pyridin-4-yl)oxy)-6-(2-methoxyethoxy)-N-methyl-1H-indole-1-carboxamide or a pharmacologically acceptable salt thereof that is to be administered in combination with an estrogen receptor antagonist or an aromatase inhibitor.